OSE fundamentals
OSE IMMUNOTHERAPEUTICS financial statements, including revenue, expenses, profit, and loss
The total revenue of OSE for the last semiannual is 69.05 M EUR, and it's 7845.45% higher compared to the previous semiannual. The net income of H1 24 is 57.17 M EUR.
0.00
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: EUR
TTM